EFFICACY AND SAFETY OF IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. AN ANALYSIS OF A COMPREHENSIVE POPULATION-BASED DATABASE

被引：0
|
作者：
Zackova, D. [1 ]
Klamova, H. [3 ]
Doubek, M. [1 ]
Pospisil, Z. [2 ]
Dvorakova, D. [1 ]
Jurcek, T. [1 ]
Moravcova, J. [3 ]
Machova, K. [3 ]
Rulcova, J. [3 ]
Dobesova, B. [1 ]
Rysava, J. [3 ]
Cetkovsky, P. [3 ]
Razga, F. [1 ]
Mayer, J. [1 ]
机构：
[1] Univ Hosp, Dept Internal Med & Hematooncol, Brno, Czech Republic
[2] Masaryk Univ, Dept Math & Stat, Brno, Czech Republic
[3] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0858
引用
收藏
页码：346 / 346
页数：1
相关论文
共 50 条
  • [31] Comparative Efficacy of First Line Treatment of Chronic Myeloid Leukaemia (CML): A Systematic Review and Meta-Analysis
    Mealing, Stuart
    Barcena, Leticia
    Vet, Ldo
    Hawkins, Neil
    Clark, James
    Davis, Catherine
    BLOOD, 2010, 116 (21) : 1408 - 1409
  • [32] Cytogenetic clonal evolution in chronic myeloid leukemia during imatinib mesylate treatment.
    Klamova, H
    Brezinova, J
    Michalova, K
    Zemanova, Z
    Trneny, M
    BLOOD, 2005, 106 (11) : 291B - 291B
  • [33] THE RELATIVE VALUE OF DASATINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT FOR CHRONIC MYELOID LEUKEMIA
    Betegon, L.
    Gilloteau, I
    Martin, P.
    Woolmore, A.
    Oyagueez, I
    VALUE IN HEALTH, 2012, 15 (07) : A420 - A420
  • [34] Treatment outcome of patients receiving imatinib for chronic myeloid leukemia as first or second line therapy
    De Souza, C. A.
    Pagnano, K. B. B.
    Delamain, M. T.
    Lorand-Metze, I.
    Miranda, E. C. M.
    Silveira, R. A.
    Metze, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 535 - 535
  • [35] Treatment outcomes in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia (CML). EVIREPRO data base analysis
    Pintos, Luis
    Catalan, Marta
    Sanabria, Alba
    Kruss, Mariana
    Bunzel, Susana
    Gatto, Paola
    Santini, Fernando
    Cinara, Luis
    Pintos, Noemi
    Lopez, Anabella
    Sgromo, Mariana
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S25 - S26
  • [36] Decisions Taken in Children and Adolescents with Chronic Myeloid Leukemia (CML) at Failure of Imatinib Treatment
    Suttorp, Meinolf
    Tauer, Josephine Tabea
    Krumbholz, Manuela
    von Neuhoff, Nils
    Schlegelberger, Brigitte
    Metzler, Markus
    Thiede, Christian
    BLOOD, 2014, 124 (21)
  • [37] Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy
    Sweet, Kendra L.
    Al Ali, Najla H.
    Lancet, Jeffrey E.
    Creelan, Ben
    Tinsley, Sara
    Shah, Bijal D.
    Zhang, Ling
    Komrokji, Rami S.
    Pinilla-Ibarz, Javier
    BLOOD, 2012, 120 (21)
  • [38] Safety and efficacy of Bosutinib in Chronoc Phase Chronic Myeloid Leukemia (CP CML)
    Bruemmendorf, T. H.
    Cortes, J.
    Schafhausen, P.
    Ordemann, R.
    Hochhaus, A.
    le Coutre, P.
    Pavlov, D.
    Leip, E.
    Duvillie, L.
    Besson, N.
    Gogat, K.
    Gambacorti-Passerini, C.
    ONKOLOGIE, 2012, 35 : 48 - 48
  • [39] Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party
    Gugliotta, Gabriele
    Castagnetti, Fausto
    Breccia, Massimo
    D'Adda, Mariella
    Stagno, Fabio
    Levato, Luciano
    Carella, Angelo Michele
    Martino, Bruno
    Tiribelli, Mario
    Cambrin, Giovanna Rege
    Gozzini, Antonella
    Salvucci, Marzia
    Cedrone, Michele
    Trabacchi, Elena
    Usala, Emilio
    Scortechini, Anna Rita
    Luciano, Luigia
    Soverini, Simona
    Alimena, Giuliana
    Cavo, Michele
    Martinelli, Giovanni
    Pane, Fabrizio
    Saglio, Giuseppe
    Baccarani, Michele
    Rosti, Gianantonio
    BLOOD, 2016, 128 (22)
  • [40] IMPACT OF AGE ON EFFICACY, SAFETY, AND LONG-TERM OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED IN FIRST-LINE WITH NILOTINIB: A GIMEMA CML WORKING PARTY ANALYSIS
    Gugliotta, G.
    Castagnetti, F.
    Breccia, M.
    D'Adda, M.
    Stagno, F.
    Levato, L.
    Carella, A. M.
    Martino, B.
    Tiribelli, M.
    Rege-Cambrin, G.
    Gozzini, A.
    Salvucci, M.
    Cedrone, M.
    Trabacchi, E.
    Usala, E.
    Scortechini, A. R.
    Luciano, L.
    Soverini, S.
    Foa, R.
    Cavo, M.
    Martinelli, G.
    Pane, F.
    Saglio, G.
    Baccarani, M.
    Rosti, G.
    HAEMATOLOGICA, 2017, 102 : 85 - +
12345